Molecule Details
| InChIKey | QLRRJMOBVVGXEJ-XHSDSOJGSA-N |
|---|---|
| Canonical SMILES | NC(=O)[C@H]1CCN(c2ncnc(N)c2F)C[C@@H]1N1CCC[C@@H](Nc2cc(Cl)cc(C(F)(F)F)c2)C1=O |
| Clinical Status | Data-mined Candidate |
| Targets (Human+Pathogen) | 2 |
| Pfam Stratification | Homologous |
| Avg pChEMBL | 8.41 |
| Source | ChEMBL;BindingDB |
2D Structure
Activity Profile
DrugBank Annotations
| DrugBank ID | DB16657 |
|---|---|
| Drug Name | Vecabrutinib |
| CAS Number | 1510829-06-7 |
| Groups | investigational |
| ATC Codes | nan |
| Description | Vecabrutinib is under investigation in clinical trial NCT03037645 (Safety, PK, PD, and Antitumor Activity of Vecabrutinib (SNS-062) in B Lymphoid Cancers). |
Categories: Amines
Cross-references: CHEMBL4297640 ChemSpider: 64835225
Target Activities (2)
DrugBank Target Actions (1)
| Target | Gene | Target Name | Action | Type |
|---|---|---|---|---|
| Q06187 | BTK | Tyrosine-protein kinase BTK | inhibitor | targets |